This is a spontaneous report received from a consumer via a nurse with the (b) (6)  
 A 67-year-old male initiated subcutaneous H.P. Acthar Gel (Acthar) 80 units twice weekly on 13-Dec-2013 
for the treatment of nephrotic syndrome. Concomitant medications were not provided.
On an unknown date, the consumer's physician informed him that his protein loss was "in the high 4,000 range 
previously, but it went up to over 13,000".  The consumer also experienced feet swelling, weight gain and diarrhea 
on unknown dates in 2014. Due to these events, Acthar was discontinued by his physician on an unknown date in 
the middle of Mar-2014. The outcome of the events was unknown. The consumer stated that, "The doctor told me 
there was a 60% chance it would work, and a 10% chance it would not work for me. I'm not sure if something else 
is going on, I am going for a kidney biopsy soon. I'm not sure if it was the Acthar or something else going on." 
Follow-up information was received on 21APR2015 from a consumer via the (b) (6)  
Print Time: 13-JAN-2016 12:03 PM If a field is blank, there is no data for that field Page 12 of 38
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
(b) (6)
. The patient reported that Acthar made his "condition/numbers" worse and "almost killed him". He 
further reported it did nothing for him. The outcome of the events was not reported.
Nephrotic syndrome worsened
Causality as reported: Related
Causality as determined: Related
Lack of effect
Causality as reported: Related
Causality as determined: Related
The consumer has reported separate events with Acthar. See manufacturer report numbers QSC-2014-0006 and 
QSC-2014-0118.